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Available online xxxxA 1-year-old girl born to consanguineous parents presented with
unexplained liver failure, leading to transplantation at 19 months.
Subsequent partial splenectomy for persistent cytopenia showed the
presence of foamy cells, and Gaucher disease was conﬁrmed by
homozygosity for the p.Leu483Pro mutation in the GBA gene. She
was treated by enzyme replacement therapy (ERT). Clinical follow-up
showed mild developmental delay, strabismus, nystagmus and oculo-
motor apraxia. Biochemical studies revealed multiple respiratory chain
deﬁciencies and a mosaic pattern of deﬁcient complex IV immunostain-
ing in liver and ﬁbroblast. Molecular analysis identiﬁed a mtDNA
depletion syndrome due to the homozygous p.Pro98Leu mutation in
MPV17. A younger sister unaffected bymtDNA depletion, presentedwith
pancytopenia and hepatosplenomegaly. ERT for Gaucher disease resulted
in visceral normalization without any neurological symptom. A third
sister, affected by both conditions, hadmarked developmental delay,
strabismus and ophthalmoplegia but no liver cirrhosis. In conclu-
sion, intrafamilal variability occurs in MPV17-related disease. The
combined pathological effect of Gaucher and mitochondrial diseasesKeywords:
Mitochondrial disease
mtDNA depletion
Gaucher disease
Neurohepatic; mtDNA, mitochondrial DNA.
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the outcome in consanguineous families. The immunocytochemical
staining of OXPHOS protein in tissues and cultured cells is a powerful
tool revealing mosaic pattern of deﬁciency pointing to mtDNA-related
mitochondrial disorders.
© 2014 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The clinical evaluation of children presenting with a progressive liver disease can be a challenging task.
Once common causes have been ruled out, mitochondrial hepatopathy is frequently considered. However,
mitochondrial enzyme activities in damaged tissues can be difﬁcult to interpret or can be misleading [1,2].
In this paper, we report on the complex diagnostic process in a family in which three sisters presented
with liver disease and neurological symptoms. Due to consanguinity, mitochondrial DNA depletion and
Gaucher disease occurred in the same sibship. Because of the presence of clinical inconsistencies regarding
each diagnostic hypothesis, both diagnoses were sequentially considered, before molecular analyses
conﬁrmed their co-occurrence.
Liver mitochondrial DNA depletion syndrome (MIM 203700, 251880, 271245, 256810) is a group of
autosomal recessive disorders characterized by progressive liver disease and encephalopathy. It is a
heterogeneous condition that can be caused by mutations in the POLG, DGUOK, PEO1 andMPV17 genes [3].
In Gaucher disease (MIM 230800), visceral involvement predominates in the spleen, but liver inﬁltration
by Gaucher cells is usually responsible for hepatomegaly and mild liver cytolysis. However, progressive
hepatopathy has been described in Gaucher disease, eventually leading to cirrhosis [4,5]. In addition, type
3 Gaucher disease (MIM231000) is also responsible for neurological involvement including developmental
delay and supranuclear gaze palsy [6]. Thus, mitochondrial DNA depletion and Gaucher have both a
neuro-hepatic pathologic pattern. In this report, we discuss the contribution of each disease to the differential
clinical involvement of three sisters.
2. Methods
2.1. Biochemical analyses
Respiratory chain complex enzyme activities were measured in frozen liver (patients 1, 2 and 3), frozen
muscle (patients 1 and 3) and culturedﬁbroblasts (patient 1) by spectrophotometry, as previously described [7].
2.2. Cytological and histological analyses
The immunocytochemical staining of cultured skin ﬁbroblasts and parafﬁn-embedded liver was carried
out as published [8], the latter adjusted for detection with the Envision G/2 AP permanent red System
(Dako, Glostrup, Denmark) according to the manufacturer's speciﬁcations. The concentration of primary
antibodies against complex I (MTND6) and complex IV (MTCO1) was 2 μg/ml (Life Technologies, Carlsbad,
CA, USA). For immunoﬂuorescent staining, cells were incubated with 25 ng/ml Mitotracker Red CMXRos
(Life Technologies) after which they were ﬁxed in 3.5% paraformaldehyde and permeabilized in ice-cold
acetone. Subsequently, slides were incubated with monoclonal antibodies directed against complex IV
(MTCO1) and AlexaFluor488-labeled secondary antibody (Life Technologies). Slides were mounted with
vectashield containing DAPI to counterstain cell nuclei (Vector Laboratories, Burlingame, CA, USA).
2.3. Molecular studies
DNA was extracted from muscle and blood according to standard puriﬁcation protocols (Chemagen,
Perkin Elmer, Zaventem, Belgium). All coding exons and the relevant ﬂanking intronic nucleotides of the
MPV17 gene were Sanger sequenced using the BigDye Terminator Cycle Sequencing kit (v.3.1) according
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Merelbeke, Belgium). DNA sequences were aligned with the reference sequence NM_002437.4.
Themitochondrial genome content inmuscle tissuewas determined by real time quantitative polymerase
chain reaction using speciﬁc primers for the mitochondrial transfer RNA leucine (MTTL1) and the nuclear
single copy beta-2-microglobulin gene (TaqMan probe and primers available on request). The PCR reactions
were done in triplicate using the TaqManUniversal PCRMasterMix system (Life Technologies) on an Applied
Biosystems 7500 real-time Sequence Detection System. The relative quantiﬁcation of mtDNA/nuclear
DNA ratio was determined by the comparative threshold cycle (CT) method. The depletion of mtDNA was
determined by comparing the patient's mtDNA amounts with that of tissue and age matched controls [9].
2.4. Case reports
2.4.1. Patient 1
A 10-year-old girl, born from consanguineous Moroccan parents, presented since the age 3 months
with progressive hepatosplenomegaly and mild liver cytolysis. The common causes for hepatitis were
ruled out and metabolic investigations showed mild but persistent excretion of 3-methylglutaconate,
3-methylglutarate and ethylmalonate, suggesting possible mitochondrial dysfunction. Biopsies revealed
liver cirrhosis with cholestasis and microvesicular steatosis. Respiratory chain studies measured in a liver
biopsy sample showed a deﬁciency of complex I, complex III and complex IV (Table 1). Progressive liver
failure and cirrhosis led to liver transplantation performed at the age of 19 months.
During the year following the liver transplantation, splenomegaly becamemore obvious and accompanied
by severe anemia and thrombocytopenia. Bone marrow examination, performed twice, was normal. At
3 years of age, partial splenectomy was performed and histological analysis revealed the presence of
foamy cells considered as consistent with Gaucher's cells (Fig. 1). Gaucher disease was conﬁrmed by low
glucocerebrosidase activity and presence of the homozygous c.1448 T N C (p.Leu483Pro)mutation in theGBA
gene, usually associated with type 3 Gaucher disease. Enzyme replacement therapy (ERT) was started by
imiglucerase at the dose of 60 U/kg, followed by normalization of hematological parameters. Clinical
follow-up showed failure to thrive, developmental delay and mild cerebellar ataxia. Unaided walk was
achieved at the age of 3 years. Fine motor control was impaired by clumsiness. She also presented with
nystagmus, strabismus, paucity of facial movement and progressive external ophthalmoplegia. Nevertheless,
she made progress, and at age 10 years, she was able to attend normal school with support.
2.4.2. Patient 2
The young sister of patient 1 was born at the time of the patient 1 transplantation. At the age of two,
she was admitted for an acute episode of abdominal pain. She had major hepatosplenomegaly andTable 1
OXPHOS activities in different tissues from the patients measured by spectrophotometric analysis.
Tissue Patient Complex
I/CS
Complex
II/CS
Complex II +
III/CS
Complex
III/CS
Complex
IV/CS
Citrate
synthase⁎
Skeletal
muscle
P1 0.53 (−1,83) 0.61 (−1.75) 0.59 (−2.25) 0.78 (−1.57) 0.89 (−1.83) 270
P3 0.63 (−0.17) 0.69 (0.25) 0.61 (−1.75) 0.79 (−1.43) 0.89 (−1.83) 190
Controls (n = 30) 0.64 ± 0.06 0.68 ± 0.04 0.68 ± 0.04 0.89 ± 0.07 1.00 ± 0.06 174 ± 70
Liver P1 0.26 (−3.46) 0.89 (−1.73) 0.39 (−5.25) 0.46 (−6.00) 0.57 (−3.92) 219
P2 0.78 (0.54) 1.10 (0.18) 0.84 (0.37) 1.00 (0.00) 1.04 (0.00) 126
P3 0.53 (−1.38) 0.93 (−1.36) 0.56 (−3.13) 0.72 (−3.11) 0.71 (−2.75) 165
Controls (n = 22) 0.71 ± 0.13 1.08 ± 0.11 0.81 ± 0.08 1.00 ± 0.09 1.04 ± 0.12 79 ± 32
Cultured skin
ﬁbroblasts
P1 ND 0.64 (0.60) 0.63 (−0.43) 0.72 (−2.14) 0.83 (−2.60) 120
Controls (n = 30) ND 0.61 ± 0.05 0.66 ± 0.07 0.87 ± 0.07 0.96 ± 0.05 82 ± 15
Activities are considered deﬁcient when the Z-score is b−3.0 and are shown in bold.
Abbreviations: CS: citrate synthase; ND: not done.
⁎ Speciﬁc activity is expressed as nanomoles of substrate per minute per milligram of protein. All other data are expressed as the
logarithm of OXPHOS activity divided by the logarithm of citrate synthase activity. Control sample ratios, shown in italics, are given
as mean ± SD. The Z-scores, values inside parentheses, are calculated as the activity ratio for the patient sample minus the mean
activity ratio for the control samples divided by the SD for the control samples.
BA C
Fig. 1. Spleen resection—Patient 1. The spleen's sinusoids are ﬁlled with groups of macrophages (A, hematoxylin–eosin, original
magniﬁcation ×8). At higher magniﬁcation (B, hematoxylin-eosin, original magniﬁcation ×30 and C, PAS staining, original
magniﬁcation ×20), the macrophages have a greyish ﬁbrillary cytoplasm, weakly positive for PAS.
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She was treated by ERT (imiglucerase), allowing rapid and complete normalization of hematological
abnormalities and progressive disappearance of visceral storage. Psychomotor development was
completely normal. Aged of eight, ataxia, strabismus and ophthalmoplegia were not present.
2.4.3. Patient 3
A third sister was systematically screened at age 3 months. She had mild hepatomegaly without
splenomegaly. Gaucher's disease was rapidly conﬁrmed by molecular analysis and ERT started before severe
hematological abnormalities occurred. Despite early treatment, she had mild persistent hepatomegaly and
mild chronic liver cytolysis. She also was found to be hypotonic with psychomotor delay, strabismus,
intermittent nystagmus and ophthalmoplegia. Metabolic screening was normal, including urinary organic
acid chromatography and blood lactate in basal condition. An oral glucose tolerance testwas performed at age
1 year which showed normal proﬁle, without hyperlactatemia. Liver biopsies showed steatosis, an oncocytic
appearance of some hepatocytes in addition to the presence of Gaucher cells (Fig. 2). Currently aged 3.5 years,
she has speech delay and severe mental and motor delay (unable to walk unaided). Neurologic examination
shows persistent axial hypotonia,moderate lower limb stiffness, paucity of facialmovementwith trismus and
near complete ophthalmoplegia. She has no clinical signs of cirrhosis, and liver ultrasound examination does
not reveal liver heterogeneity or portal hypertension.
Tissue biopsies and molecular studies were performed with informed consent of the parents.
3. Results
3.1. Biochemical analyses
Respiratory chain analysis in liver biopsy samples from patients 1 and 3 showed a combined deﬁciency
of the respiratory chain complex I, complex III and complex IV. Respiratory chain analyses in skeletal
muscle and ﬁbroblasts were normal (Table 1).
3.2. Cytological and histological analyses
Immunocytological examination in cultured skin ﬁbroblasts from patient 1 revealed a mosaic pattern
for complex IV, while staining of the other complexes was normal. This has been described to represent a
A B
Fig. 2. Liver biopsy—Patient 3. The liver parenchyma shows steatosis together with granular red, oncocytic hepatocytes in periportal
areas, suggestive of mitochondriopathy. Small aggregates of macrophages characteristic of Gaucher disease (arrows) are also
recognizable within the sinusoids (A, hematoxylin–eosin, original magniﬁcation ×10), better underlined after PAS staining (B, PAS
staining, original magniﬁcation ×26).
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a reduction of the mitotracker signal (Fig. 3A) accompanied by heterogeneous immunodetection of
complex IV, i.e., cells staining negative alongside positive cells with varying staining intensities (Fig. 3B).
Also, as clearly seen in the composed image (Fig. 3C), red and green staining is segregated in some cells,
pointing to the presence of mitochondria lacking mitochondrial membrane potential build-up.
Immunostaining on liver biopsies revealed a mosaic pattern of deﬁcient complex IV staining in patient
1 (Figs. 4A, C), consistent with the mtDNA depletion. By contrast, immunostaining in patient 2, unaffected
by the mtDNA depletion syndrome, was normal (Figs. 4B, D).
3.3. Molecular studies
A severe mtDNA depletion was identiﬁed in liver of patient 1, as the residual mtDNA content in this
depleted tissue was only 16%. Muscle and liver tissues of the sisters were not available for molecular assay.
Liver mtDNA depletion was a strong indication for an underlying molecular defect in the POLG, DGUOK or
MPV17 genes. Analyses of both POLG and DGUOK genes in patient 1 showed no pathogenic mutation.
Conversely, sequence ofMPV17 gene revealed a homozygous c.293C N T mutation (p.Pro98Leu). Patient 3
was also homozygous for this mutation whereas both parents and patient 2 were heterozygotes.
4. Discussion
The ﬁnal accurate diagnosis was difﬁcult to establish in this family because of multiple pitfalls. First,
although the results of enzymes activitymeasurement in the liver biopsy pointed to amitochondrial disorder,
the subsequent diagnosis of Gaucher disease raised question about a possible non speciﬁc secondary
respiratory chain dysfunction in the cirrhotic liver, and molecular investigations for mitochondrial diseases
were not performed at this time. Conversely, before the ﬁnding of foamy cells, splenomegaly could have been
interpreted as a manifestation of portal hypertension, without consideration for a storage disorder. In
addition, bonemarrow examinationswere not informative, and Gaucher cells were eventually identiﬁed only
in the spleen. Finally, progressive neurological impairment led to reevaluation for a mitochondrial disorder,
even though the neurological disease could be explained by type 3 Gaucher disease. Immunocytological
stainingwas performed at this stage. The ﬁnding of amosaic pattern of complex IV deﬁciency in cultured skin
ﬁbroblasts and liver tissue sustained the possibility of a mtDNA-related disease, and the quantiﬁcation of
Fig. 3. Immunoﬂuorescent studies in ﬁbroblasts. Cultured skin ﬁbroblasts from patient 1 (A–C) and an age-matched healthy control (D–F). Mitotracker in red shows reduced staining in the patient
(A). Complex IV immunostaining in green shows reduction and heterogeneity in the patient's cells (B). Panel C shows segregation of staining: the presence of complex IV positive mitochondria
(green) that lack mitochondrial membrane potential sensitive Mitotracker staining. Cell nuclei were stained with DAPI (blue in all panels). Panels D to F show normal staining in a control cell line.
Scale bars =50 μm.
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Fig. 4. Immunohistochemical staining for complex IV MTCO1 in parafﬁn-embedded liver tissues. Immunostaining of complex IV in
the liver of patient 1 (A, C) and patient 2 (B, D), visualized with permanent red (pink), nuclei were counterstained with hematoxylin
(blue). Liver of patient 1 displays a mosaic staining pattern (left panels), while normal staining is observed in patient 2 (right
panels). Scale bars = 200 μm (A–B) 50 μm (C–D).
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diagnosis. AmosaicmtDNAdepletion in cultured skinﬁbroblasts has been recently reported inMPV17disease
[11]. For the ﬁrst time, we show that this mosaic pattern of deﬁciency can be also observed by immunostaining
for respiratory chain complexes in ﬁbroblasts and liver. This case highlights the need for exhaustive
investigations in complex multisystemic disorders.
Patient 1 presented with severe liver disease, leading to transplantation. Progressive liver disease and
cirrhosis can occur in Gaucher disease [4,5], although uncommonly. The precise pathogenesis of hepatic
dysfunction in Gaucher disease is unknown. Gaucher disease is predominantly a disease of macrophages, and
the liver contains the largest organ bulk of tissue macrophages. Disturbances of sphingolipid metabolism in
hepatic Gaucher cells may induce dysregulation of cellular inﬂammatory pathways, aberrant cytokine
production and secondary ﬁbrosis and hepatic dysfunction. In this proband, hepatopathy was most likely
caused by mtDNA depletion, as MPV17-related disorders are usually characterized by infantile-onset liver
dysfunction that typically progresses to liver failure [11–13]. This hypothesis was even reinforced by the fact
that the second sister, presenting Gaucher disease without mtDNA depletion, had no liver disease. However,
one can speculate that concomitant Gaucher disease caused a cumulative injury in the liver already affected by
mitochondrial hepatopathy, eventually leading to ﬁbrosis and cirrhosis. Indeed, untreated Gaucher disease in
patient 1 could have had a negative impact because she presented liver failure at age 18 months, whereas the
youngest sister, treated by ERT since the age of 4 months, did not develop progressive liver disease, at least until
the current age of 3.5 years. Liver transplantation is the only therapeutic option in case ofMPV17-related liver
failure. However, it is associated with a signiﬁcant mortality rate and does not prevent evolution of neurologic
symptoms [12,13]. The current favorable outcome of patient 1 suggests that some patients remain candidate
for liver transplantation. Regarding Gaucher disease, liver transplantation has been reported in exceptional
cases presenting end-stage liver disease and was associated with an excellent outcome [14]. However, all
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activitywithin donormacrophages of the transplanted livermay give a beneﬁcial effectwithin the transplanted
organ itself [14]. Interestingly, the presence of donor cells has been demonstrated in the skin, intestine, bone
marrow and lymph node of Gaucher disease patients 26 months post-transplantation, indicating postallograft
microchimerism [15].
The p.Pro98Leumutation inMPV17 identiﬁed in our patients has been previously reported in combination
with another mutation in a 2.5-year-old girl, presenting with typical neuro-hepatic disease [16]. The same
mutation has also been reported in the homozygous state in a 21-year-old man presenting with neuropathy
and leukoencephalopathy [17] and in a 25-year-old woman presenting with secondary amenorrhea,
megaloblastic anemia, lactic acidosis, leukoencephalopathy, peripheral neuropathy and liver cirrhosis [18].
These late-onset cases suggest that this mutation could be a milder allele responsible for attenuated or, at
least, delayed phenotypes. Perhaps this accounts for the absence of early progressive liver disease in the
youngest sister, and the currently relatively favorable outcome in the oldest transplanted girl.
The most difﬁcult question is to delineate the respective implications of Gaucher disease and mtDNA
depletion syndrome in the neurological involvement of these patients. On one hand, except in the Navajo
population of the southwestern United States, MPV17 is usually responsible for marked developmental
delay, infantile hypotonia, muscle weakness and peripheral neuropathy, leading to severe encephalomyop-
athy. However, as discussed previously, the speciﬁc homozygotemutation identiﬁed in our patients has been
reported with later onset cases, albeit in only two patients [17,18]. On the other hand, the p.Leu483Pro
mutation in the homozygote state is the most common genotype associated with the subacute neuropathic
form (type 3b) of Gaucher disease [19,20]. In that case, patients usually also present with motor and mental
delay. In addition, saccadic initiation delay, oculomotor apraxia and early onset horizontal gaze palsy typically
occur in type 3 Gaucher disease [6,21]. Pyramidal tract signs, trismus and bulbar signs can be present,
including stridor, swallowing difﬁculties and paucity of facial movement [6]. Rotary nystagmus and
opsoclonus are typical manifestations of hepatic mtDNA depletion syndrome caused by DGUOK mutations
[22], but oculomotor abnormalities were not reported inMPV17-related disorders.
Overall, the neurological phenotype of patients 1 and 3 is well explained by type 3b Gaucher, which is
consistent with their GBA genotype. However, patient 2 who is only affected by Gaucher disease has a
completely normal motor and mental development and her neurological examination is strictly normal.
Despite her GBA genotype, the phenotype of patient 2 looks like type 1, raising question about genotype–
phenotype correlations in Gaucher disease. It is also possible that ERT started early in infancy may have
slowed down progression of neurological lesions in this patient. However, the effects of ERT on neurological
involvement in Gaucher disease has not been ﬁrmly established [23].
In conclusion, a wide clinical variability occurs in the neurohepatic involvement observed in this family.
This variability is tentatively explained by the combined effects of two autosomal recessive metabolic
disorders. The differential effect of each disease on the patient's phenotypes is difﬁcult to determine and a
cumulative negative impact of mitochondrial and lysosomal diseases is hypothesized. However, variability
remains incompletely understood. Multiple recessive disorders should be considered in consanguineous
families with complex phenotypes.References
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